Stocksigma LogoStocksigma Logo

Vaishali Pharma Reports Nil Deviation in Utilization of Preferential Issue Proceeds

Vaishali Pharma Limited confirmed zero deviation or variation under Regulation 32 of SEBI Listing Regulations for the quarter ended 30th Sep'26

Vaishali Pharma Reports Nil Deviation in Utilization of Preferential Issue Proceeds

Vaishali Pharma Ltd · Others (Uncategorized) · 15 Nov 2026, 1:15 am

Vaishali Pharma Reports Nil Deviation in Utilization of Preferential Issue Proceeds Vaishali Pharma Limited confirmed zero deviation or variation under Regulation 32 of SEBI Listing Regulations for the quarter ended 30th Sep'26. The company fully utilized the entire preferential issue proceeds of ₹9,07,57,300 raised on 3rd Jul'26 via share swap. The funds were deployed entirely toward part-funding the acquisition of equity shares in Kesar Pharma Limited to expand its pharmaceutical product portfolio, realize strategic synergies, and enhance shareholder value. The Audit Committee and Board reviewed and approved the statement on 14th Nov'26 without adverse remarks.

Original exchange filing (PDF)

More announcements from Vaishali Pharma Ltd

All Vaishali Pharma Ltd announcements